| abstract |
Provided is a polypeptide which specifically binds to the γ-chain of human interleukin-2 receptor to selectively inhibit the binding of the γ-chain of human interleukin-2 receptor to the β-chain of the same, therefore having an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the objective polypeptide by incubating the transformant. The novel polypeptide is usable, independently or along with substances capable of inhibiting the binding of interleukin-2 to interleukin-2 receptor, as a medicine effective in preventing the rejection of grafts after transplantation and also in curing inflammatory diseases such as allergic diseases and autoimmune diseases, the possibility that interleukin-2 will actively participate in the rejection and also in such inflammatory diseases having been suggested. |